The following LIMR-developed IP and technologies are available for licensing. To learn more, please contact LIMR at 484.476.8000 or email info@limr.org.

Cancer

Targeted nano-carrier therapeutics for precision medicine

Principal investigator: Janet Sawicki, PhD

Taking a new precision medicine approach, LIMR researchers have developed a safe and effective nanocarrier-based therapy that specifically targets ovarian tumor cells and blocks a central mechanism of drug resistance (siHuR-3DNA). Preclinical proof of concept suggests that targeting this mechanism via this nanocarrier agent may offer safe and effective treatment of a variety of solid tumors exhibiting drug resistance.

Therapeutics that block polyamine action, suppress tumor growth

Principal investigator: Susan Gilmour, PhD

Polyamines are ubiquitous, small molecules that are essential for all cell growth and proliferation. Tumors maintain dramatically elevated levels of polyamines to support their growth and survival. A novel class of proprietary polyamine-transport inhibitors has been shown by Dr. Gilmour to suppress tumor growth in preclinical studies. These inhibitors not only deprive tumor cells of polyamines, they also relieve polyamine-mediated immunosuppression in the tumor microenvironment.

Combination therapy using IDO inhibitors to eliminate tumor vasculature

Principal investigator: Alexander Muller, PhD

LIMR’s technology encompasses new uses of IDO inhibitors to enhance the activity of anti-angiogenic or antimetabolic drugs used to treat cancer or in other disease settings where ablation of a pathogenic blood vasculature is desired.

Blood test to predict risk of chemotherapy-induced nausea

Principal investigator: U. Margaretha Wallon, PhD

Nausea after chemotherapy is a much-feared side effect. Yet not all patients experience it to the same degree, or even at all. Dr. Wallon developed a blood-based assay that can predict which patients will experience post-chemotherapy nausea. With that information, physicians can prescribe the right dosage of antiemetics to the right patients at the right time for a truly precision-medicine approach to patient treatment.

IDO/TDO pro-drug inhibitors

Principal investigator: Alexander J. Muller, PhD and George C. Prendergast, PhD

LIMR’s collaborative team has created the first pro-drug class of small molecule inhibitors that can be tuned to inhibit various subsets of the known IDO/TDO enzymes, representing new structure of matter for clinical development.


Autoimmune disease

Treatment of autoimmune disorders with RhoB antibodies

Principal investigators: Lisa Laury-Kleintop, PhD and Laura-Mandik-Nayak, PhD

Building on long-standing studies of the disease-promoting small GTPase RhoB, including in selectively driving production of autoantibodies, LIMR scientists have developed a cell-permeable anti-RhoB antibody that exhibits therapeutic efficacy in preclinical models of rheumatoid arthritis, lupus and diabetes. In principle, this invention affords a general strategy for treating autoimmune disorders driven by autoantibody production as a single class by administering a single biologic agent directed against a nodal signal transduction modifier. LIMR’s innovative approach incorporates the leading edge in targeting intracellular antigens generally considered inaccessible to antibody-based therapies.

Treatment of inflammatory bowel disease with Bin1 antibodies

Principal investigator: Sunil Thomas, PhD

Building on their expertise in tissue barrier functions of the gastrointestinal tract, LIMR scientists have now developed an antibody-based therapy that inactivates a molecule that facilitates gut inflammation in the setting of IBD.

Treatment of rheumatoid arthritis and autoimmune disorders with IDO2 antibodies

Principal investigator: Laura Mandik-Nayak, PhD and Lisa Laury-Kleintop, PhD

The immunomodulatory enzyme IDO2, discovered by LIMR scientists, has been identified as an essential mediator of autoimmune disease. In preclinical models of rheumatoid arthritis (RA), systemic administration with a cell-permeable monoclonal antibody developed at LIMR that specifically binds IDO2 in B cells reduced the level of autoreactive T and B cell activation and alleviated pathogenic symptoms. LIMR’s investigators have defined a pathway that allows for effective targeting of intracellular antigens previously considered inaccessible to antibody-based therapies.


Gastrointestinal

Blood test to distinguish inflammatory bowel disease from inflammatory bowel syndrome

Principal investigator: Thomas Stamato, PhD

With no well-established standards to accurately diagnose IBD, there is a need for biomarkers that are cost-effective, rapid and provide insight into individual disease complexity and biology. In addressing the need for a non-invasive assessment of IBD in patients presenting with IBS, LIMR scientists have developed a blood test that may make this determination as an aid to improving personalized care.


Monoclonal antibody cloning

Mammalian antibody display technology

Principal investigator: Scott Dessain, MD, PhD

The Center for Human Antibody Technology (CHAT) is a facility at LIMR that uses a powerful human antibody cloning platform technology developed by Dr. Dessain. CHAT uses this platform along with a state-of-the-art, high throughput antibody production and screening facility to produce human antibodies for use in the treatment of infectious disease, cancer and neurological illnesses. CHAT can help academic investigators create their own human antibody therapeutics.


Ocular diseases

Novel treatments for macular degeneration

Lead investigators: Lisa Laury-Kleintop, PhD, and Alexander J. Muller, PhD

LIMR researchers have defined new medicinal uses for two classes of drugs that could treat ocular diseases such as wet macular degeneration, diabetic retinopathy, macular edema, diabetic macular edema, and myopic choroidal neovascularization.